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JOURNAL OF HEPATOLOGYReply to ‘‘The problem of the most appropriate curative treatment for
hepatocellular carcinoma. When to embolize? When to operate?’’surgical resection, nonsurgical approaches can be considered in
clinical practices for several reasons, such as patient refusal to
undergo surgical resection, old age, relatively poor performance
status, accompanying co-morbidities, evidence of portal hyper-
tension, high indocyanine green retention test at 15 min, high
liver stiffness value assessed using transient elastography [4,5],
and inappropriate location for surgical resection based on the
remnant liver volume.
The major aim of our study was to assess the impact of achiev-
ing a complete response (CR) at an early time point among
patients with HCC treated with transarterial chemoembolization
(TACE), not to compare the clinical outcomes between treatment
modalities. When we stratiﬁed the 298 patients without tumor
invasion of the peripheral portal vein branches into three groups;
patients within the Milan criteria [3], patients beyond the Milan
criteria, but within the up-to-seven criteria [6], and patients
beyond the up-to-seven criteria, the patients within the Milan
criteria had the highest CR rate (initial response, 82.9%), followed
by those beyond the Milan criteria, but within the up-to-seven
criteria (59.2%) (p <0.001 vs. those within the Milan criteria),
and those beyond the up-to-seven criteria (13.7%) (p <0.001 vs.
those beyond the Milan criteria, but within the up-to-seven crite-
ria). Similarly, in the view of achieving a CR as the best response,
patients within the Milan Criteria had the highest CR rate of
88.6%, followed by those beyond the Milan criteria, but within
the up-to-seven criteria with 74.5% (p = 0.009 vs. those within
the Milan criteria) and those beyond the up-to-seven criteria
with 40.0% (p <0.001 vs. those beyond the Milan, but within the
up-to-seven criteria) (Table 1). We agree that better clinical out-
comes are anticipated after TACE in patients with a smaller tumor
burden, but the prognostic signiﬁcance of achieving a CR as the
initial and best response was also observed in all three sub-
groups. Patients who achieved a CR (both initial and best
response) had a longer median overall survival than the othersTo the Editor:
We appreciate the valuable comments by Guerra et al. on our
recently published article [1]. They raised some issues.
We recognize that surgical resection should be considered
ﬁrst, provided that patients are clinically eligible for this
approach when considering liver function, portal pressure, rem-
nant liver volume after surgical resection, and performance sta-
tus. Vitale et al. [2] indicated that surgical resection can prolong
survival compared with loco-regional therapy in patients with
hepatocellular carcinoma (HCC), regardless of the Barcelona
Clinic Liver Cancer (BCLC) stage, provided that liver dysfunction
(Child-Pugh Class B or Model for End-stage Liver Disease score
>9) and poor performance status (Eastern Cooperative Oncology
Group >1) are absent. Indeed, it is more important to identify
optimal candidates who will beneﬁt from multi-disciplinary
approaches rather than offering a formulaic treatment modality.
Accordingly, nonsurgical approaches can also be considered in a
patient with early stage HCC to avoid the risk of postoperative
complications, including hepatic insufﬁciency and mortality, par-
ticularly for those with a morphologically cirrhotic liver on a pre-
operative radiological assessment. In this clinical setting,
orthotopic liver transplantation (OLT) is a better option than sur-
gical resection as it manages the underlying cirrhotic liver and
HCC simultaneously. However, OLT is often ineligible due to the
shortage of appropriate donors in South Korea.
Approximately, one-third of our study participants had a
tumor burden within the Milan criteria [3], i.e., BCLC early stage,
in which surgical resection or OLT may be recommended accord-
ing to the degree of underlying liver disease. Surgical resection
should be performed with caution in highly selected patients
with BCLC early stage HCC and a morphologically cirrhotic liver,
if they do not receive a suitable graft quickly. Furthermore,
although patients who show BCLC early stage HCC and morpho-
logically non-cirrhotic liver may be obviously good candidates forJournal of Hepatology 2015 vol. 63 j 276–288 281
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in the subgroup within the Milan criteria (Log-rank test, p <0.05).
Similar results were obtained in the subgroup beyond the Milan
criteria but within the up-to-seven criteria and the subgroup
beyond the up-to-seven criteria (Log-rank test, all p <0.05).
Taken together, although we demonstrated the clinical signif-
icance of the response to TACE at an early time point, further
studies are required for extended applications of surgical resec-
tion in patients with BCLC B stage HCC as well as those with
BCLC A stage HCC and Child-Pugh A class liver function, but a
morphologically cirrhotic liver.
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Reduced mortality due to phlebotomy in moderately iron-loaded
HFE haemochromatosis? The need for clinical trials
To the Editor:
We read with interest the paper by Bardou-Jacquet and col-
leagues [1] examining mortality in HFE-associated hemochro-
matosis and the accompanying editorial [2]. Both the authors of
the study and the writers of the editorial concluded that the
observation that HFE p.C282Y homozygotes with a serum ferritin
(SF) at diagnosis between the upper limit of normal (ULN) and
1000 lg/L have reduced mortality compared to the population
at large is predominantly due to venesection therapy.
We are not convinced however, that this conclusion is sup-
ported by the data provided for the following reasons:
1. If normalization of SF resulted in reduced mortality then it
would be expected that HFE p.C282Y homozygotes with nor-
mal SF at diagnosis would also have reduced mortality but this
was not found to be the case.
2. There was no information about the amount of iron removed
for 36% of subjects so there was likely to be a signiﬁcant
minority of individuals with SF between the ULN and
1000 lg/L who did not have normalization of SF.
3. The cohort had a follow-up mean duration of 8.3 ± 3.9 years.
The average age at diagnosis was 45.2 ± 14.2 years. This means
that it is likely that many subjects in the group with SF
between the ULN and 1000 lg/L had a raised SF for many
more years than they had a normalized SF. It is not at all clear
how this balance would result in reduced mortality when this
was not seen among those with normal SF at diagnosis. Of
those who did have information about the amount of iron
removed, there is no information about whether they contin-
ued venesection therapy in order to maintain a SF level
<50 lg/L after a SF of <50 lg/L was achieved initially, or the
extent to which follow-up data (number and volume of phle-
botomies, clinical and biochemical indicators of tolerance and
efﬁcacy of venesection therapy) were available. Moreover,
there is no information about a formal, standardized, consis-
tent, cohort-wide protocol around advising participants to
start, continue and potentially stop venesection therapy,
which makes the claim that the results can be interpreted as
‘‘intention-to-treat’’ difﬁcult to justify.
Reasons other than the beneﬁt of normalization of SF that
could explain the study ﬁndings include:
1. Having a mild excess of iron in the body reduces the risk of
cardiovascular and extra-hepatic cancer. This is counter intui-
tive with data suggesting that iron is a pro-oxidant and there-
fore more likely to result in increased cancer incidence. In
addition we found an increase in the incidence of breast and
colorectal cancer in a large cohort of HFE p.C282Y homozy-
gotes compared to a matched HFE wild-type control group,
we did not, however, have sufﬁcient data to examine the
association of cancer occurrence with SF levels [3]. From the
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